XERS Stock Recent News

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time. A live webcast of the event will be available on the 'Events & Presentations.

Xeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter, with total product revenue surging 25% compared to the previous year's quarter. Paul Edick, CEO of Xeris, cited significant momentum in Recorlev sales, the steadfastness of Keveyis in the market, and the expanding market share of Gvoke as key drivers of the firm's performance over the quarter.

Xeris Biopharma (XERS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.

Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing diabetes management. The partnership seeks to leverage Xeris' novel XeriSol technology for the development and commercialization of a glucagon product to be integrated into Beta Bionics' proprietary bi-hormonal pump and pump systems.

Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis.

Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing borrowing interest rates. Under this agreement, Xeris secured $200 million in capital upfront, with the option to access an additional $15.2 million to redeem its outstanding convertible senior notes due in 2025.

Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:00 am Eastern Time. To access the presentation, please v.

Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.